GlassScriptPhysician profile
Melissa M Carry
NPI 1386618510
$1,676.96
in general payments reported to CMS, 2019-2025
21 companies · $86.53 in 2025
The $86.53 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $42.65 · 2021: $13.64 · 2022: $275 · 2023: $462 · 2024: $678 · 2025: $86.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $347.22 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $277.16 | 2022-2024 | Camzyos, Eliquis |
| Medtronic, INC. | $228.65 | 2023-2025 | Corevalve Evolut R, Symplicity G3, Cobalt Dr Mri Surescan |
| Pfizer INC. | $180.23 | 2019-2023 | |
| Novo Nordisk INC | $75.22 | 2022-2024 | Ozempic, Rybelsus |
| Innovation Technologies INC | $64.30 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.43 | 2023-2024 | Lifevest |
| Amgen INC. | $52.43 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $49.91 | 2022-2024 | Xarelto |
| Heartflow, INC. | $45.15 | 2019 | |
| Merck Sharp & Dohme LLC | $44.09 | 2022-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $41.20 | 2019-2024 | |
| Cvrx, INC. | $37.60 | 2022-2023 | Barostim Neo System |
| Tactile Systems Technology INC | $35.69 | 2023 | Entre Plus, Flexitouch Plus |
| Boston Scientific Corporation | $29.24 | 2023-2025 | Enhance Transcarotid Peripheral Access Kit, Watchman Access System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $26.37 | 2019 | |
| Itamar Medical INC | $23.63 | 2023 | Watchpatone |
| Kiniksa Pharmaceuticals International, Plc | $21.42 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $18.15 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $15.11 | 2023 | Praluent, Evkeeza |
| Siemens Medical Solutions USA, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Carry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.